Article Text

AB0140 Relationship between Expression of Synovial B Cell Survival Factors and Clinical Response to Rituximab Treatment in Rheumatoid Arthritis
  1. R. Thurlings1,
  2. M. Boumans1,
  3. W. de Jager2,
  4. K. Vos1,3,
  5. L. van Baarsen1,
  6. D. Gerlag1,
  7. B. Prakken2,
  8. P.P. Tak1
  1. 1Academic Medical Center/University of Amsterdam, Amsterdam
  2. 2University Medical Center of Utrecht, Utrecht
  3. 3Flevoziekenhuis, Almere, Netherlands


Background Rituximab aims to deplete CD20 positive B cells and exerts a significant and often long-lasting clinical effect in a subset of patients with rheumatoid arthritis (RA). The extent of B cell depletion in the inflammatory tissues after rituximab varies between patients and persistence of plasma cells and plasma cell products is associated with clinical non-response. This suggests rituximab may fail to deplete pathogenic B cells.

Objectives To investigate whether the variable clinical response to rituximab might be explained by differential expression of B cell survival factors in the inflamed synovial tissue of RA patients.

Methods Twenty-four RA patients underwent an arthroscopic synovial biopsy before, 1 month after and 4 months after treatment with rituximab. Treatment was given via two infusions (1,000 mg on day 1 and 15), both without methylprednisolon premedication to be able to study specific biological effects of rituximab. Clinical response was defined as a response according to the European League Against Rheumatism (EULAR) criteria at week 24. Peripheral blood and synovial tissue were analyzed for expression and levels of B cell survival factors: BLyS, APRIL, IL-1β, IL6, BLyS, VCAM, ICAM, IFNα, CXCL12 and BLIMP1. Correlation between baseline expression and changes in B cell survival factors and clinical response were calculated using logistic regression analysis.

Results We found no significant correlation between baseline expression level of synovial B cell survival factors and clinical response to treatment. After treatment, the expression levels of BLyS, APRIL, IL-1β, IL6, ICAM and BLIMP1 were unaltered. The expression of IFNα and VCAM decreased after treatment, of which VCAM within one month (P =0.035, P =0.022 and P =0.039, respectively). In contrast, expression of CXCL-12 increased after treatment (P =0.046). In clinical responders VCAM expression decreased further between 1 and 4 months after treatment, although a statistical significant difference with non-responders could not be detected.

Conclusions Clinical non-response to rituximab is not associated with a higher baseline expression of B cell survival factors in the inflamed synovial tissue of RA patients. However, the persistent expression of survival factors independent of the extent of B cell depletion may promote the persistence of pathogenic B cell subsets in clinical non-responders to treatment.

Acknowledgements Het Reumafonds

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.5312

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.